Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects
Simon Pernot1, Magali Terme2, Aziz Zaanan1
1Service d'Hépatogastro-entérologie et d'oncologie digestive, Hôpital Européen Georges-Pompidou, Université Paris Descartes, 20, rue Leblanc, 75015 Paris, France.
Abstract:
Squamous cell carcinoma of the anus (SCCA) is a rare disease, but its incidence has been increasing dramatically since the 1970s. Men who have sex with men (MSM) and infection with human immunodeficiency virus (HIV) are the two main risk factors. Risk of developing SCCA is increased more than 100-fold in HIV-seropositive MSM. We review here how immunodeficiency could promote SCCA and how restoration of immunity since the advent of combined antiretroviral therapy can influence the natural history and incidence of SCCA. We also review the prognostic and therapeutic implications of immunosuppression in these patients. Finally, we show how, with anti-HPV vaccines, immunity is a target in the prevention of SCCA and could in the future be used in its treatment.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Cellular Adaptation IV: Dysplasia and Metaplasia
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis


